Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice

Neurobiology of Disease

Volumn 91, Issue , 2016, Pages 21-36

  Martella, G ^a,b   Madeo, G ^a,b   Maltese, M ^a   Vanni, V ^b   Puglisi, F ^b   Ferraro, E ^b   Schirinzi, T ^a   Valente, E M ^c   Bonanni, L ^d   Shen, J ^e   Mandolesi, G ^b   Mercuri, N B ^a,b   Bonsi, P ^b   Pisani, A ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Electrophysiology; Mitochondria; Parkinson's disease; PINK1 heterozygous mutations; Rotenone; Striatum; Synaptic plasticity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; CYTOCHROME C; DOPAMINE; ROTENONE; TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20; TROLOX C; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME RELEASE; GENE; GENE MUTATION; HETEROZYGOSITY; KNOCKOUT MOUSE; LONG TERM DEPRESSION; LONG TERM EXPOSURE; LONG TERM POTENTIATION; MEDIUM SPINY NEURON; MITOCHONDRION; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PINK1 GENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; WILD TYPE; ANIMAL; DRUG EFFECTS; GENETICS; HETEROZYGOTE; METABOLISM; SYNAPSE;

ANIMALS; CORPUS STRIATUM; DOPAMINE; HETEROZYGOTE; LONG-TERM POTENTIATION; MICE, KNOCKOUT; NEURONAL PLASTICITY; NEURONS; PROTEIN KINASES; ROTENONE; SUBSTANTIA NIGRA; SYNAPSES;

EID: 84960848269     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.12.020     Document Type: Article

References (77)

1. Abou-Sleiman P.M., Muqit M.M., McDonald N.Q., Yang Y.X., Gandhi S., Healy D.G., Harvey K., Harvey R.J., Deas E., Bhatia K., Quinn N., Lees A., Latchman D.S., Wood N.W. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann. Neurol. 2006, 60(4):414-419.
2. Albanese A., Valente E.M., Romito L.M., Bellacchio E., Elia A.E., Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 2005, 64(11):1958-1960.
3. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl. 2000, 59:133-154.
4. Alberto M.E., Russo N., Grand A., Galano A. A physicochemical examination of the free radical scavenging activity of Trolox: mechanism, kinetics and influence of the environment. Phys. Chem. Chem. Phys. 2013, 15(13):4642-4650.
5. Ascherio A., Chen H., Weisskopf M.G., O'Reilly E., McCullough M.L., Calle E.E., Schwarzschild M.A., Thun M.J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 2006, 60(2):197-203.
6. Bellinger F.P., Bellinger M.T., Seale L.A., Takemoto A.S., Raman A.V., Miki T., Manning-Boğ A.B., Berry M.J., White L.R., Ross G.W. Glutathione peroxidase 4 is associated with neuromelanin in substantia nigra and dystrophic axons in putamen of Parkinson's brain. Mol. Neurodegener. 2011, 6:8.
7. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3(12):1301-1306.
8. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21(17):6853-6861.
9. Binkofski F., Reetz K., Gaser C., Hilker R., Hagenah J., Hedrich K., van Eimeren T., Thiel A., Büchel C., Pramstaller P.P., Siebner H.R., Klein C. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007, 69(9):842-850.
10. Bonanni L., Chachar M., Jover-Mengual T., Li H., Jones A., Yokota H., Ofengeim D., Flannery R.J., Miyawaki T., Cho C.H., Polster B.M., Pypaert M., Hardwick J.M., Sensi S.L., Zukin R.S., Jonas E.A. Zinc-dependent multi-conductance channel activity in mitochondria isolated from ischemic brain. J. Neurosci. 2006, 26(25):6851-6862.
11. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300(2):535-543.
12. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp. Neurol. 2013, 246:72-83.
13. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30(5):211-219.
14. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34(2):279-290.
15. Cheng H.C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 2010, 67:715-725.
16. Cheng H.C., Kim S.R., Oo T.F., Kareva T., Yarygina O., Rzhetskaya M., Wang C., During M., Talloczy Z., Tanaka K., Komatsu M., Kobayashi K., Okano H., Kholodilov N., Burke R.E. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J. Neurosci. 2011, 31(6):2125-2135.
17. Chou J.S., Chen C.Y., Chen Y.L., Weng Y.H., Yeh T.H., Lu C.S., Chang Y.M., Wang H.L. (G2019S)LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol. Dis. 2014, 68:190-199.
18. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135(Pt 7):2058-2073.
19. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29(11):3365-3373.
20. Cicchetti F., Drouin-Ouellet J., Gross R.E. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol. Sci. 2009, 30(9):475-483.
21. Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 2005, 6:889-898.
22. Eggers C., Schmidt A., Hagenah J., Brüggemann N., Klein J.C., Tadic V., Kertelge L., Kasten M., Binkofski F., Siebner H., Neumaier B., Fink G.R., Hilker R., Klein C. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010, 74:1798-1805.
23. Ferraro E., Pulicati A., Cencioni M.T., Cozzolino M., Navoni F., di Martino S., Nardacci R., Carrì M.T., Cecconi F. Apoptosome-deficient cells lose cytochrome c through proteasomal degradation but survive by autophagy-dependent glycolysis. Mol. Biol. Cell 2008, 19(8):3576-3588.
24. Fiorio M., Valente E.M., Gambarin M., Bentivoglio A.R., Ialongo T., Albanese A., Barone P., Pellecchia M.T., Brancati F., Moretto G., Fiaschi A., Tinazzi M. Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. J. Neurol. 2008, 255(9):1372-1377.
25. Galvin J.E., Uryu K., Lee V.M., Trojanowski J.Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. U. S. A. 1999, 13450-5.
26. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(32):11364-11369.
27. George S., Mok S.S., Nurjono M., Ayton S., Finkelstein D.I., Masters C.L., Li Q.X., Culvenor J.G. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. J. Mol. Neurosci. 2010, 42(2):243-254.
28. Giordano T.P., Satpute S.S., Striessnig J., Kosofsky B.E., Rajadhyaksha A.M. Up-regulation of dopamine D(2)L mRNA levels in the ventral tegmental area and dorsal striatum of amphetamine-sensitized C57BL/6 mice: role of Ca(v)1.3 L-type Ca(2+) channels. J. Neurochem. 2006, 99(4):1197-1206.
29. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45(4):489-496.
30. Harris J.J., Jolivet R., Attwell D. Synaptic energy use and supply. Neuron 2012, 75(5):762-777.
31. Hatcher J.M., Pennell K.D., Miller G.W. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol. Sci. 2008, 29(6):322-329.
32. Hoepken H.H., Gispert S., Morales B., Wingerter O., Del Turco D., Mülsch A., Nussbaum R.L., Müller K., Dröse S., Brandt U., Deller T., Wirth B., Kudin A.P., Kunz W.S., Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 2007, 25(2):401-411.
33. Inden M., Kitamura Y., Abe M., Tamaki A., Takata K., Taniguchi T. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol. Pharm. Bull. 2011, 34(1):92-96.
34. Janc O.A., Müller M. The free radical scavenger Trolox dampens neuronal hyperexcitability, reinstates synaptic plasticity, and improves hypoxia tolerance in a mouse model of Rett syndrome. Front. Cell. Neurosci. 2014, 8:56.
35. Janezic S., Threlfell S., Dodson P.D., Dowie M.J., Taylor T.N., Potgieter D., Parkkinen L., Senior S.L., Anwar S., Ryan B., Deltheil T., Kosillo P., Cioroch M., Wagner K., Ansorge O., Bannerman D.M., Bolam J.P., Magill P.J., Cragg S.J., Wade-Martins R. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(42):E4016-E4025.
36. Johnson M.E., Bobrovskaya L. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2015, 46:101-116.
37. Kamsler A., Segal M. Hydrogen peroxide modulation of synaptic plasticity. J. Neurosci. 2003, 23:269-276.
38. Kessler K.R., Hamscho N., Morales B., Menzel C., Barrero F., Vives F., Gispert S., Auburger G. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. J. Neural Transm. 2005, 112(10):1345-1353.
39. Khan N.L., Valente E.M., Bentivoglio A.R., Wood N.W., Albanese A., Brooks D.J., Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 2002, 52:849-853.
40. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
41. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(27):11441-11446.
42. Kitada T., Pisani A., Karouani M., Haburcak M., Martella G., Tscherter A., Platania P., Wu B., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice. J. Neurochem. 2009, 110(2):613-621.
43. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher M.G., Lang A.E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007, 6(7):652-662.
44. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136(Pt 8):2419-2431.
45. Li Q., Lau A., Morris T.J., Guo L., Fordyce C.B., Stanley E.F. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J. Neurosci. 2004, 24(16):4070-4081.
46. Madeo G., Schirinzi T., Martella G., Latagliata E.C., Puglisi F., Shen J., Valente E.M., Federici M., Mercuri N.B., Puglisi-Allegra S., Bonsi P., Pisani A. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov. Disord. 2014, 29(1):41-53.
47. Marongiu R., Ferraris A., Ialongo T., Michiorri S., Soleti F., Ferrari F., Elia A.E., Ghezzi D., Albanese A., Altavista M.C., Antonini A., Barone P., Brusa L., Cortelli P., Martinelli P., Pellecchia M.T., Pezzoli G., Scaglione C., Stanzione P., Tinazzi M., Zecchinelli A., Zeviani M., Cassetta E., Garavaglia B., Dallapiccola B., Bentivoglio A.R., Valente E.M., Italian PD Study Group PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum. Mutat. 2008, 29:565. [serial online].
48. Martinez T.N., Greenamyre J.T. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signal. 2012, 16(9):920-934.
49. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997, 79(2):323-327.
50. Morais V.A., Verstreken P., Roethig A., Smet J., Snellinx A., Vanbrabant M., Haddad D., Frezza C., Mandemakers W., Vogt-Weisenhorn D., Van Coster R., Wurst W., Scorrano L., De Strooper B. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1(2):99-111.
51. Moretti M., Budni J., Dos Santos D.B., Antunes A., Daufenbach J.F., Manosso L.M., Farina M., Rodrigues A.L. Protective effects of ascorbic acid on behavior and oxidative status of restraint-stressed mice. J. Mol. Neurosci. 2013, 49(1):68-79.
52. Morton D.B., Griffiths P.H. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet. Rec. 1985, 116(16):431-436.
53. Mulchay P., O'Doherty A., Paucard A., O'Brien T., Kirik D., Dowd E. The behavioral and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behav. Brain Res. 2013, 243:6-15.
54. Murakami S., Miyazaki I., Sogawa N., Miyoshi K., Asanuma M. Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice. Neurotox. Res. 2014, 26(3):285-298.
55. Napolitano F., Pasqualetti M., Usiello A., Santini E., Pacini G., Sciamanna G., Errico F., Tassone A., Di Dato V., Martella G., Cuomo D., Fisone G., Bernardi G., Mandolesi G., Mercuri N.B., Standaert D.G., Pisani A. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiol. Dis. 2010, 38(3):434-445.
56. Nicholls D.G. Oxidative stress and energy crises in neuronal dysfunction. Ann. N. Y. Acad. Sci. 2008, 1147:53-60.
57. Ogawa N., Asanuma M., Kondo Y., Kawada Y., Yamamoto M., Mori A. Differential effects of chronic l-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci. Lett. 1994, 171(1-2):55-58.
58. Ott M., Robertson J.D., Gogvadze V., Zhivotovsky B., Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(3):1259-1263.
59. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441(7097):1157-1161.
60. Puglisi F., Vanni V., Ponterio G., Tassone A., Sciamanna G., Bonsi P., Pisani A., Mandolesi G. Torsin A localization in the mouse cerebellar synaptic circuitry. PLoS ONE 2013, 8(6):e68063.
61. Rao V.K., Carlson E.A., Yan S.S. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim. Biophys. Acta 2014, 1842:1267-1272.
62. Reetz K., Tadic V., Kasten M., Brüggemann N., Schmidt A., Hagenah J., Pramstaller P.P., Ramirez A., Behrens M.I., Siebner H.R., Klein C., Binkofski F. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol. Dis. 2010, 39(3):402-408.
63. Ricciardi L., Petrucci S., Guidubaldi A., Ialongo T., Serra L., Ferraris A., Spanò B., Bozzali M., Valente E.M., Bentivoglio A.R. Phenotypic variability of PINK1 expression: 12 years' clinical follow-up of two Italian families. Mov. Disord. 2014, 29(12):1561-1566.
64. Rice M.E. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 2000, 23(5):209-216.
65. Richardson J.R., Shalat S.L., Buckley B., Winnik B., O'Suilleabhain P., Diaz-Arrastia R., Reisch J., German D.C. Elevated serum pesticide levels and risk of Parkinson disease. Arch. Neurol. 2009, 66(7):870-875.
66. Richter F., Hamann M., Richter A. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J. Neurosci. Res. 2007, 85(3):681-691.
67. Rizzoli S.O. Synaptic vesicle recycling: steps and principles. EMBO J. 2014, 33(8):788-822.
68. Schapira A.H. Mitochondrial pathology in Parkinson's disease. Mt Sinai J. Med. 2011, 78(6):872-881.
69. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54(3):823-827.
70. Shim J.H., Yoon S.H., Kim K.H., Han J.Y., Ha J.Y., Hyun D.H., Paek S.H., Kang U.J., Zhuang X., Son J.H. The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion 2011, 11(5):707-715.
71. Slemmer J.E., Shacka J.J., Sweeney M.I., Weber J.T. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr. Med. Chem. 2008, 15(4):404-414.
72. Surmeier D.J., Plotkin J., Shen W. Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 2009, 19(6):621-628.
73. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119(6):866-872.
74. Traber M.G., Stevens J.F. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic. Biol. Med. 2001, 51(5):1000-1013.
75. van Nuenen B.F., Weiss M.M., Bloem B.R., Reetz K., van Eimeren T., Lohmann K., Hagenah J., Pramstaller P.P., Binkofski F., Klein C., Siebner H.R. Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 2009, 72:1041-1047.
76. Wang X., Quinn P.J. Vitamin E and its function in membranes. Prog. Lipid Res. 1999, 38(4):309-936.
77. Zharikov A.D., Cannon J.R., Tapias V., Bai Q., Horowitz M.P., Shah V., El Ayadi A., Hastings T.G., Greenamyre J.T., Burton E.A. ShRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest. 2015, 125(7):2721-2735.